share_log

Ginkgo Bioworks | DEFA14A: Others

Ginkgo Bioworks | DEFA14A: Others

Ginkgo Bioworks | DEFA14A:其他
美股sec公告 ·  04/29 16:04
Moomoo AI 已提取核心信息
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has announced the nomination of Myrtle Potter and Ross Fubini as independent directors for election at the company's annual meeting on June 13, 2024. The announcement comes as current Board Chair Marijn Dekkers and Nominating and Corporate Governance Committee Chair Reshma Kewalramani are set to retire and not seek reelection. CEO Jason Kelly expressed gratitude for the outgoing members' contributions and enthusiasm for the incoming nominees' expertise. Potter has a significant background in pharmaceutical R&D and corporate leadership, including roles at Sumitomo Pharma America and Genentech. Fubini brings experience from the venture capital sector, having founded XYZ Venture Capital and supported numerous companies. The nominations are part of Ginkgo Bioworks' ongoing efforts to enhance its board's capabilities in cell programming and biosecurity. The company is a leader in providing services across various markets, including food, agriculture, pharmaceuticals, and industrial chemicals. The press release also contains forward-looking statements regarding the potential election of the new directors and the company's future plans.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has announced the nomination of Myrtle Potter and Ross Fubini as independent directors for election at the company's annual meeting on June 13, 2024. The announcement comes as current Board Chair Marijn Dekkers and Nominating and Corporate Governance Committee Chair Reshma Kewalramani are set to retire and not seek reelection. CEO Jason Kelly expressed gratitude for the outgoing members' contributions and enthusiasm for the incoming nominees' expertise. Potter has a significant background in pharmaceutical R&D and corporate leadership, including roles at Sumitomo Pharma America and Genentech. Fubini brings experience from the venture capital sector, having founded XYZ Venture Capital and supported numerous companies. The nominations are part of Ginkgo Bioworks' ongoing efforts to enhance its board's capabilities in cell programming and biosecurity. The company is a leader in providing services across various markets, including food, agriculture, pharmaceuticals, and industrial chemicals. The press release also contains forward-looking statements regarding the potential election of the new directors and the company's future plans.
Ginkgo Bioworks Holdings, Inc.(纽约证券交易所代码:DNA)宣布提名默特尔·波特和罗斯·富比尼为独立董事,将在2024年6月13日的公司年会上进行选举。该公告发布之际,现任董事会主席玛丽恩·德克斯和提名与公司治理委员会主席雷什玛·凯瓦尔拉马尼即将退休,不寻求连任。首席执行官杰森·凯利对离任成员的贡献表示感谢,并对新候选人的专业知识表示热情。Potter 在药物研发和企业领导方面拥有丰富的背景,包括在美国住友制药和基因泰克任职。Fubini带来了风险投资领域的经验,他创立了XYZ风险资本并支持了许多公司。这些提名是Ginkgo Bioworks为提高其董事会在细胞编程和生物安全方面的能力所做的持续努力的一部分。该公司在为食品、农业、药品和工业化学品等各个市场提供服务方面处于领先地位。新闻稿还包含有关新董事可能当选和公司未来计划的前瞻性陈述。
Ginkgo Bioworks Holdings, Inc.(纽约证券交易所代码:DNA)宣布提名默特尔·波特和罗斯·富比尼为独立董事,将在2024年6月13日的公司年会上进行选举。该公告发布之际,现任董事会主席玛丽恩·德克斯和提名与公司治理委员会主席雷什玛·凯瓦尔拉马尼即将退休,不寻求连任。首席执行官杰森·凯利对离任成员的贡献表示感谢,并对新候选人的专业知识表示热情。Potter 在药物研发和企业领导方面拥有丰富的背景,包括在美国住友制药和基因泰克任职。Fubini带来了风险投资领域的经验,他创立了XYZ风险资本并支持了许多公司。这些提名是Ginkgo Bioworks为提高其董事会在细胞编程和生物安全方面的能力所做的持续努力的一部分。该公司在为食品、农业、药品和工业化学品等各个市场提供服务方面处于领先地位。新闻稿还包含有关新董事可能当选和公司未来计划的前瞻性陈述。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息